Tariffs, Trade Wars, and the Risk to Drug Access

The global pharmaceutical industry has long been built on a foundation of cross-border integration. Active pharmaceutical ingredients (APIs), finished drugs, and medical devices flow across multiple geographies before reaching U.S. patients. This distributed model delivers cost efficiencies and access to innovation, but also leaves the sector vulnerable to sudden policy shifts. The imposition of tariffs on imported pharmaceuticals and their components, as proposed under recent U.S. trade policies, represents one of the most significant disruptions to this ecosystem in decades. We analyze the implications of escalating tariffs particularly those imposed under the Trump administration on the pharmaceutical industry. The consequences are multifaceted: rising production costs, disrupted supply chains, reduced access to affordable medicines, and long-term strategic reorientation of where and how companies manufacture. At the center of the issue is the United States’ reliance on imports, particularly from India and China, which collectively supply more than 70% of APIs used in U.S. drugs and nearly 50% of the generics market.

In 2024, the U.S. imported $215 billion worth of pharmaceutical goods, up sharply from $73 billion in 2014, illustrating just how deeply integrated the industry has become with global manufacturing. Tariffs, even at 25%, have the potential to increase domestic drug prices by nearly 13% and add an estimated $51 billion annually to U.S. healthcare costs. More extreme measures such as the proposed 200% or 245% tariffs on Chinese APIs risk triggering shortages of essential drugs, as companies may struggle to absorb the costs or to relocate production to domestic facilities. For patients, this means higher costs, reduced insurance coverage, and increased barriers to access. For companies, it means revisiting procurement strategies, building redundancy into their supply chains, and lobbying governments for trade carve-outs.